Predicting Impacts of the Pending COVID-19 Vaccination Campaign on Safety Reporting, Tracking, and Liability for the Entire Industry

Predicting Impacts of the Pending COVID-19 Vaccination Campaign on Safety Reporting, Tracking, and Liability for the Entire Industry

Whitepapers

This whitepaper, developed in partnership with Sidley Austin LLP, provides an in-depth analysis of the impact of the COVID-19 mass vaccination campaigns on pharmacovigilance teams, including:

  • The mass influx of adverse events reported within a short period of time
  • The need for rapid signal evaluation and impact assessments
  • Increased liability risks given the prominence and scale of the vaccination programs

Download this whitepaper to learn why pharmacovigilance departments for all pharmaceutical companies, regardless of whether they are a COVID-19 manufacturer, must be prepared for the anticipated surge in adverse event reporting.

Cookies

We use analytical cookies that need your permission. For more details and advanced options view our Cookies Policy.

DeclineAccept